Yushiro Yamasihta

Prof. Yushiro Yamasihta

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
YYYushiro Yamasihta
Yushiro Yamasihta
CFChizu Fujimoto
Chizu Fujimoto
ENEisuke Nakajima
Eisuke Nakajima
TITakeo Isagai
Takeo Isagai
TMToyojiro Matsuishi
Toyojiro Matsuishi

1 September 2000 in Brain and Development
Verified
Journal Article
Closed access
PDF file
NWNaoko Wada
Naoko Wada
YYYushiro Yamasihta
Yushiro Yamasihta
TMToyojiro Matsuishi
Toyojiro Matsuishi
YOYasuyo Ohtani
Yasuyo Ohtani
HKHirohisa Kato
Hirohisa Kato

28 January 2016 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
TYTadahiro Yanagi
Tadahiro Yanagi
TMTatsuki Mizuochi
Tatsuki Mizuochi
YTYugo Takaki
Yugo Takaki
KEKeisuke Eda
Keisuke Eda
KMKeiichi Mitsuyama
Keiichi Mitsuyama
KYKen Yamamoto
Ken Yamamoto
Although deleterious mutations in interleukin-10 and its receptor molecules cause severe infantile-onset inflammatory bowel disease, there are no reports of mutations affecting this signaling pathway in Japanese patients. Here we report a novel exonic mutation in the IL10RA gene that caused unique splicing aberrations in a Japanese patient with infantile-onset of inflammatory bowel disease in association with immune thrombocytopenic purpura and a transient clinical syndrome mimicking juvenile myelomonocytic leukemia. A Japanese boy, who was the first child of non-consanguineous healthy parents, developed bloody diarrhea, perianal fistula, and folliculitis in early infancy and was diagnosed with inflammatory bowel disease. He also developed immune thrombocytopenic purpura and transient features mimicking juvenile myelomonocytic leukemia. The patient failed to respond to various treatments, including elemental diet, salazosulfapyridine, metronidazole, corticosteroid, infliximab, and adalimumab. We identified a novel mutation (c.537G > A, p.T179T) in exon 4 of the IL10RA gene causing unique splicing aberrations and resulting in lack of signaling through the interleukin-10 receptor. At 21 months of age, the patient underwent allogeneic hematopoietic stem cell transplantation and achieved clinical remission. We describe a novel exonic mutation in the IL10RA gene resulting in infantile-onset inflammatory bowel disease. This mutation might also be involved in his early-onset hematologic disorders. Physicians should be familiar with the clinical phenotype of IL-10 signaling defects in order to enable prompt diagnosis at an early age and referral for allogeneic hematopoietic stem cell transplantation.

1 December 2001 in Brain and Development
Verified
Journal Article
Closed access
PDF file
YYYushiro Yamasihta
Yushiro Yamasihta
IKIkuko Kondo
Ikuko Kondo
TFTakayuki Fukuda
Takayuki Fukuda
RMRiyo Morishima
Riyo Morishima
AKAkira Kusaga
Akira Kusaga
TMToyojiro Matsuishi
Toyojiro Matsuishi

1 September 1995 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
YHYukiko K Hayashi
Yukiko K Hayashi
RKRitsuko Koga
Ritsuko Koga
TTToshifumi Tsukahara
Toshifumi Tsukahara
HIHiroko Ishii
Hiroko Ishii
TMToyojiro Matsuishi
Toyojiro Matsuishi
KAKiichi Arahata
Kiichi Arahata

1 January 2013 in Child and Adolescent Psychiatry and Mental Health
Verified
Journal Article
Open access
PDF file
MUMasahide Usami
Masahide Usami
DSDaimei Sasayama
Daimei Sasayama
NSNobuhiro Sugiyama
Nobuhiro Sugiyama
NHNana Hosogane
Nana Hosogane
SKSoo-Yung Kim
Soo-Yung Kim
KSKazuhiko Saito
Kazuhiko Saito
The aim of this study was to evaluate the reliability and validity of the Questionnaire-Children with Difficulties (QCD), which was developed for the evaluation of children’s daily life behaviors during specified periods of the day.